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The green tea amino acid, L-theanine (L-THE) is associated with several health benefits, including 36 
improvements in mood, cognition and a reduction of stress and anxiety-like symptoms. This systematic 37 
review evaluated the effect of pure L-THE intake, in the form of orally administered nutritional 38 
supplements, on stress responses and anxiety levels in human randomised controlled trials. Following 39 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist, nine 40 
peer-reviewed journal articles were identified where L-THE as a supplement was compared to a 41 
control. Our findings suggest that supplementation of 200–400 mg/day of L-THE may assist in the 42 
reduction of stress and anxiety in people exposed to stressful conditions. Despite this finding, longer-43 
term and larger cohort clinical studies, including those where L-THE is incorporated into the diet 44 
regularly, are needed to clinically justify the use of L-THE as a therapeutic agent to reduce stress and 45 
anxiety in people exposed to stressful conditions. 46 
 47 
Keywords: L-theanine, stress response, anxiety, mental health, green tea, human trials 48 
 49 
Abbreviations 50 
L-THE L-Theanine 51 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses  52 
RCT Randomised Controlled Trial 53 
HPA Hypothalamic Pituitary Adrenal 54 
HR Heart Rate 55 
HRV Heart Rate Variability 56 
POMS Profile of Mood States  57 
VAS Visual Analog Scale  58 
STAI State-Trait Anxiety Inventory  59 
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BAI Beck’s Anxiety Inventory  60 
MAPS Mood, Alertness and Physical Symptoms Questionnaire 61 
DASS Depression Anxiety and Stress Scale  62 
VPT Visual Probe Task  63 
VAMS Visual Analogue Mood Scale   64 
HARS Hamilton Anxiety Rating Scale  65 
sAA salivary Alpha-Amylase (sAA) 66 
s-IgA Salivary Immunoglobulin A  67 
BP Blood Pressure 68 
 69 
Introduction 70 
Stress and anxiety are two inter-related conditions that have a substantial impact on individuals, 71 
communities and wider society, with 264 million people estimated to be living with anxiety disorders 72 
in 2015 [1]. The terms ‘stress’ or a ‘stressor’ are commonly used to describe physical or psychological 73 
responses to a perceived threat to homeostasis, as well as referring to a range of physiological 74 
parameters necessary for survival. Additionally, these terms can also characterise an event, or series 75 
of events, that cause a response, whether it be positive or negative [2]. In this paper, stress will be used 76 
to describe the physiological response that is detrimental to an individual that in turn, elicits a 77 
physiological and behavioural response.  78 
Prolonged stress is related to a number of chronic conditions and diseases, including hypertension 79 
[3], type 2 diabetes and coronary heart disease [4]. Furthermore, the effects of psychological stress are 80 
associated with anxiety-related diseases, including eating disorders [5], irritable bowel syndrome [6] 81 
and substance abuse [7]. The evaluation of the stress response, as well as the severity of anxiety,  can 82 
effectively be divided into two broad categories relating to L-THE; subjective psychological measures 83 
using a variety of questionnaires and assessment tools [8-11]; and physiological responses such as 84 
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changes in blood pressure (BP), circulating hormones and salivary hormones, heart rate (HR), heart 85 
rate variability (HRV) and autonomic nervous system reactivity [12-14]. In recent years, the use of 86 
complementary therapies to treat anxiety and stress-related disorders has increased; with mixed 87 
evidence surrounding their efficacy [15]. One such approach is the use of green tea, which has a long 88 
history of being consumed to enhance relaxation [16]. 89 
The consumption of green tea in some of the most densely populated countries in the world, 90 
such as China and Japan, accounts for around 20% of global consumption  [17]. In recent years the 91 
popularity, as well as the significant research interest that green tea has attracted, is typically attributed 92 
to its favourable taste as well as numerous proposed health benefits including neuroprotection [18], 93 
cholesterol-lowering properties [19-21], strong antioxidant capacity [22] whereby consumption is 94 
associated with successful aging [23,24]. Among the many constituents found in green tea such as 95 
polyphenols [25], flavonoids [26] and caffeine [27], L-Theanine (L-THE) in particular, has received 96 
considerable interest in human trials [28,29]. 97 
L-THE was first isolated and identified in 1949 [30] as a water-soluble non-proteinogenic 98 
amino acid predominantly found in the tea plant (Camellia sinensis), and responsible for the provision 99 
of a unique taste similar to the savoury taste sensation that monosodium glutamate produces known as 100 
‘umami’ [28,31]. According to the universal nomenclature of the International Union of Pure and 101 
Applied Chemistry, L-THE is ‘2-amino-4-(ethylcarbamoyl) butyric acid’ and it is referred to by many 102 
different names including ‘gamma-glutamylethylamide’ and ‘gamma-glutamyl-L-ethyl amide’ [32] 103 
reflecting the presence of glutamine, a conditionally essential amino acid found as a core unit in its 104 
structure [29]. The theanine may occur as a racemic mix of its L- and D- enantiomers that compete for 105 
absorption and urinary excretion with D- enantiomer reported to be metabolised at a faster rate while 106 
L- being preferentially metabolised by the kidneys [29,33]. 107 
Studies in animal models have reported the decline of serum glucose, insulin and urea after the 108 
administration of L-THE [34]. Therefore it was proposed that L-THE may be transported into systemic 109 
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circulation by sodium-glucose transport protein 1; a mediator of glucose and galactose absorption 110 
[34,35]. Furthermore, kinetic studies indicate that L-THE crosses the blood brain barrier via the amino 111 
acid L transport-system as determined by the decrease of other L-system serum amino acids in its 112 
presence [36].  113 
The potential health benefits associated with the consumption of L-THE include improvements 114 
in emotional status, quality of sleep [29,37], suppression of hypertension [38], and improvements in 115 
mood and cognition [39]. Additionally, consumption of L-THE in combination with caffeine promotes 116 
antioxidant and anti-inflammatory activity in the brain that may reduce the risk of cognitive 117 
impairment [40]. The current evidence on the consumption of L-THE in humans and its effects on 118 
stress and anxiety is equivocal. To date, the majority of evidence is based on animal research, which 119 
has commonly used pure L-THE, and in combination with other bioactives such as caffeine [41] and 120 
catechins that can potentially have synergistic and in some cases potentially antagonistic effects 121 
[16,28]. 122 
To our knowledge, only one systematic review has investigated the effects of green tea 123 
consumption on mood and cognition [39]. Nonetheless, it is important to note that this review 124 
evaluated the effects of L-THE as well as a mixture of other tea components (catechins and caffeine) 125 
rather than L-THE in its pure form. Therefore, this systematic review aimed to evaluate the effects of 126 
L-THE consumption on anxiety levels and the stress response in humans. A secondary aim was to 127 
provide insight into the potential mechanism of action that L-THE can pose and its possible therapeutic 128 




Standardised criteria for conducting and reporting systematic reviews of interventional studies was 133 
followed based on the PRISMA 2009 statement and checklist [42]. This systematic review was 134 
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registered in an International Prospective Register of Systematic Reviews (PROSPERO); registration 135 
number CRD42018104792.  136 
1.1.  137 
Eligibility criteria 138 
A PICOS (population, intervention, comparator, outcomes and setting) approach was used to structure 139 
the systematic review and is as follows: 140 
Population: Human populations of all ages, either healthy or with a diagnosis of anxiety and/or 141 
depression were included. 142 
Intervention: Randomised controlled trials (RCTs) or quasi-RCTs that reported the effects of L-THE 143 
consumption on anxiety and stress outcomes were included. Trials were required to evaluate orally 144 
administered L-THE alone or in combination with conventional therapy versus the same conventional 145 
therapy alone. This criterion also included studies where quantifiable levels of L-THE were delivered 146 
as part of a supplement or if it was a functional component of a supplement that may also contain other 147 
compounds (i.e. food and drinks). Only studies with sample sizes of over 10 participants were included 148 
to limit the influence of outliers and allow for a more robust analysis of the results. 149 
Comparator:  Using a placebo, active control (i.e. a pharmaceutical product) or other control in single 150 
or double-blind human interventions. 151 
Outcomes: Only studies that reported pre- and post-levels of stress and/or anxiety using at least one 152 
validated psychological assessment method were included. The primary outcomes of interest included 153 
levels of anxiety and/or stress determined using a variety of scales such as the Profile of Mood States 154 
(POMS) [8], Visual Analog Scale (VAS) [9], State-Trait Anxiety Inventory (STAI) [10], and Beck’s 155 
Anxiety Inventory (BAI) [11]. Secondary outcomes were physiological responses including BP, skin 156 
temperature, HR, HRV, cortisol and salivary immunoglobulin A (s-IgA) [29].  157 
Setting: Any.  158 
7 
 
Literature search 159 
Only studies that were published in their entirety in the English language in peer-reviewed journals 160 
were included. Article selection was restricted to studies performed on humans (single- and double-161 
blind included) where an L-THE supplement was compared against a control.  162 
Four electronic databases (PubMed, Scopus, Cochrane Library and Web of Science) were 163 
searched for articles published from 1990 until October 2018. Articles were not selected prior to 1990 164 
due to the difficulty in synthesis and low commercial availability of L-THE as a supplement prior to 165 
this date. All retrieved articles were read in full, and where multiple publications referred to the same 166 
study, only the latest publication was used [43]. Searches were re-run prior to submission (March 167 
2019), with only one additional article included [44]. 168 
 169 
Search terminology 170 
Search terms used were ‘theanine’, ‘L-theanine’, ‘L-theanine AND stress’, ‘L-theanine AND anxiety’, 171 
‘gamma-glutamylethylamide’, ‘gamma-glutamylethylamide AND stress’, ‘gamma-172 
glutamylethylamide AND anxiety’, ‘gamma-glutamyl-L-ethyl amide’, ‘gamma-glutamyl-L-ethyl 173 
amide AND stress’, ‘gamma-glutamyl-L-ethyl amide AND anxiety’, ‘N5-ethyl-L-glutamine’, ‘N5-174 
ethyl-L-glutamine AND stress’ and ‘N5-ethyl-L-glutamine AND anxiety’. In addition, articles that 175 
included L-THE consumption and mood changes were also selected if the mood changes were 176 
measured as either stress or anxiety or both.  177 
 178 
Study selection and data extraction 179 
Two authors (J.W. and J.E.) independently reviewed the titles and abstracts and extracted data in a 180 
predefined table. The following information was extracted: the first author and year of publication; 181 
mean age, sample size, experimental intervention (regimen); control intervention (regimen); stress 182 
and/or anxiety outcome; and any adverse effects reported.  183 
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Risk of bias assessment 184 
Risk of bias in the included studies was independently assessed by two authors (J.W. and J.E.) 185 
following the Cochrane guidelines criteria [45]. The Cochrane guidelines assess the risk of bias based 186 
on seven domains: random sequence generation, allocation concealment, blinding of participants and 187 
personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting bias. 188 
Only articles with a low risk of overall bias were eligible for inclusion and any differences in opinion 189 
were resolved through discussion with a third reviewer (N.N.).  190 
 191 
Data analysis 192 
Included studies were analysed based on the measures specific to the study design; the intervention 193 
conducted; the sample size, age and gender of the participants; and various stress and anxiety 194 
outcomes. The results were recorded based on the change in the measures from baseline to post-195 
consumption values and evaluated for effectiveness with the probability value (p<0.05) considered as 196 
statistically significant. Due to the heterogeneity of the study design, setting, intervention and 197 
outcomes, a meta-analysis was not conducted. 198 
 199 
Results 200 
Study characteristics 201 
Initial search results identified 261 articles. Following removal of duplicates (n=40), reviews, letters 202 
to the editor and articles not written in English (n=177), the number of articles was reduced to 44. Nine 203 
articles [38,44,46-52] met the inclusion criteria (Figure 1). Seven studies recruited participants with 204 
no known pre-existing mental health issues, while two studies used participants with an existing mental 205 
health condition [44,49]. The total number of participants for all included studies was 270 with 134 206 
males and 88 females (Table 1). Two studies were conducted in males only [46,47], and one study did 207 
not provide the genders of its 48 participants [38].  208 
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Study designs 209 
Eight studies were designed as randomised, double-blind, placebo-controlled trials [38,44,46-210 
49,51,52] while one study used a randomised, single-blind, placebo-controlled design [50]. Five of the 211 
studies [46-48,51,52] used a crossover design with all the participants exposed to each of the 212 
experimental treatments conditions. The other four studies [38,44,49,50] used a parallel design to 213 
compare between an L-THE group and a placebo group. Seven of the studies compared L-THE to 214 
placebo while the study by Lu et al. [48] compared L-THE against a prescribed anti-anxiety 215 
pharmaceutical (Alprazolam; 1mg; Xanax®, Pharmacia and UpJohn Ltd) as well as against placebo. 216 
The study by White et al. [51] compared L-THE against a placebo in the form of a nutrient drink with 217 
(active) and without (placebo). 218 
 219 
Treatment duration and doses 220 
In six studies [38,46-48,51,52], treatments were given acutely on the day in which various tests and 221 
measurements were conducted. The other three studies were designed to test for chronic effects and 222 
involved interventions over periods between seventeen days [50] to eight weeks [44,49]. In the acute 223 
single day intervention trials, participants consumed 200 mg/day [46-48,52], while in the chronic trials, 224 
participants consumed 400 mg/day of L-THE [49,50], and only one study used 450 and 900 mg/day.   225 
 226 
Outcomes 227 
Five studies included investigated the effects of L-THE on stress and anxiety [38,47,50-52] and four 228 
studies investigated anxiety outcomes only [44,46,48,49]. The most commonly used scales to assess 229 
changes in anxiety symptoms in the included studies was the STAI [38,46-48,50,51], VAS [47,50,52], 230 
Hamilton Anxiety Rating Scale (HARS) [44,49], BAI [44,48], and POMS [52]. The Depression 231 
Anxiety and Stress Scale (DASS) was used in one study [38]. Physiological data were assessed by HR 232 
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[38,46,47], BP [38,52], HRV [47], and skin temperature [52]. Biomarkers were measured in three 233 
studies; s-IgA [47], salivary alpha-amylase (sAA) [50] and salivary cortisol [51]. 234 
 235 
Risk of bias assessment 236 
The risk of bias was assessed for all included studies (Table 2). Overall, a ‘Low’ risk of bias was 237 
observed across all domains. Some studies received an ‘Unclear’ classification due to insufficient 238 
information provided in the articles. Only one study received a ‘High’ risk classification because this 239 
study was single-blinded [50]. 240 
 241 
L-THE and stress responses 242 
In total, five studies assessed stress responses [38,47,50-52]. In the study by Yoto et al. [52], the 243 
participants performed a range of physical and mental tasks to test the acute effects of L-THE 244 
consumption on the stress response. Following randomisation, the participants were required to 245 
complete the POMS and VAS assessments, and baseline physiological measurements were taken 246 
before they ingested either L-THE (200 mg), caffeine (100 mg) or a placebo. The participants were 247 
then exposed to psychological stress load by auditory oddball target detection task (5 min) and 248 
arithmetic mental task test (10 min) twice. This was followed by the cold pressor test (immersion of 249 
hand in the slushy ice water) serving as an acute physical test. Participants were also analysed based 250 
on the change in BP after the mental tasks while given the placebo: those with BP responses above 251 
(‘high-response’) and below the mean (‘low-response’). The ‘high-response’ group consuming 200 252 
mg of L-THE had significantly lower systolic (p=0.008) and diastolic BP (p=0.006) in response to the 253 
mental tasks, but not the cold pressor test compared to placebo.  In the ‘low-response’ group, there 254 
were no treatment effects in systolic or diastolic BP in the measurement periods.  255 
The crossover trial by Kimura et al. [47] assessed the effects of L-THE (200 mg) on the stress 256 
response (20 min arithmetic task) across four conditions: 1) at the start of the experimental procedure; 257 
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2) during the experimental procedure; 3) placebo; and 4) no treatment. The s-IgA and psychological 258 
measures (STAI and VAS) were measured post-task while HR and HRV were measured continuously 259 
through the experimental sessions. The results indicated a significant interaction between condition 260 
and period for s-IgA (p<0.01), and s-IgA levels were higher under the placebo condition compared to 261 
the other conditions. In addition, the stress task increased HR under the placebo condition (p<0.05) 262 
while the L-THE conditions showed lower HR increments. The results of the HRV measurements 263 
revealed that some aspects of the HRV analysis (LF/HF) in the placebo condition were significantly 264 
higher (p<0.05) than other three conditions indicating more activation of the sympathetic nervous 265 
system during acute stress. 266 
The study by Rogers et al. [38] investigated the subjective, behavioural and physiological (BP 267 
and HR) effects of L-THE and caffeine supplementation administered alone and/or in combination. 268 
All participants received either a capsule of caffeine (250 mg) or placebo and drink containing L-THE 269 
(200 mg) or no L-THE. Participants recorded their responses using the Mood, alertness and physical 270 
symptoms (MAPS) questionnaire, BP and HR were assessed before and 40 min after the administration 271 
of the treatments. The results indicated that the systolic and diastolic BP were higher after the caffeine 272 
consumption than any other treatment combinations (p<0.05).  273 
A study by Unno et al. [50] examined the effects of L-THE in pharmacy students during a 274 
highly stressful period, the first week of pharmacy practice placement. Students were randomly 275 
assigned L-THE twice daily (400 mg/day) or a placebo for 17 days, with the STAI performed before 276 
and after their placement and sAA measured twice (morning and evening) daily. The results indicated 277 
that the sAA was higher in the placebo group (p=0.032) while the L-THE group maintained the 278 
baseline observed during the routine activities at the university. Interestingly, the STAI values were 279 
not different between the two groups; however, the psychosocial stress was lower in L-THE group 280 
(p=0.020) compared to placebo.  281 
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The crossover trial by White et al. [51] investigated the anti-stress effects of L-THE (200 mg) 282 
administered in the form of an L-THE active nutrient beverage commercially available (NeuroBliss®) 283 
in comparison to a placebo in 34 healthy participants (15 males, 19 females) [51]. This study carried 284 
out a multi-tasking framework as a cognitive stressor and as a cognitive assessment. In total, 285 
participants completed the task three times per visit (baseline, during and three hours post-286 
consumption). Stress, mood, fatigue and salivary cortisol were assessed prior to and following the 287 
completion of each step of the cognitive stressor. The consumption of L-THE was associated with a 288 
decrease in subjective stress responses (p=0.003) and reduced self-rated stress response (p=0.006) 289 
measured 1 hr post-administration. No significant differences were reported in the subjective stress 290 
response 3 hr after consumption; however, salivary cortisol levels were significantly lower in the L-291 
THE group (p=0.047) in comparison to placebo at this time point.  292 
 293 
Effect of L-THE on anxiety 294 
All studies [38,44,46-52] assessed the effects of L-THE on anxiety. The study by Ritsner et al. [49] 295 
explored the effect of eight weeks of L-THE (400 mg) treatment on patients with schizophrenia or 296 
schizoaffective disorders as an add-on to conventional antipsychotic therapy with anxiety levels 297 
measured using the HARS. The consumption of L-THE was associated with a reduction in total HARS 298 
score (p=0.015) with onset of improvement after the second week, and improvement in five of the 299 
HARS items including anxious mood (p=0.003), tension (p=0.021), intellectual (p=0.044), muscular 300 
(p=0.012) and sensory somatic complaints (p=0.030) in comparison to placebo group.  301 
Lu et al. [48] compared the short term effects between the L-THE (200 mg),  Alprazolam (1 302 
mg; Xanax®, Pharmacia and UpJohn Ltd) and placebo on behavioural measures of anxiety in healthy 303 
participants. There was no difference between L-THE and placebo on the STAI and BAI scores (All 304 
p’s>0.05); however, L-THE reduced subjective anxiety in comparison with Alprazolam (p<0.05) and 305 
placebo (p<0.05) on the ‘Troubled’ subscale of the VAMS. Also, VAMS-Tranquil scores were lower 306 
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for L-THE group compared to the other two treatments (All p’s>0.05). In addition, L-THE intake 307 
reduced the total HARS score (p=0.015). Furthermore, the results indicated that neither L-THE nor 308 
Alprazolam showed any acute anxiolytic effects under an electric shock model of anticipatory anxiety.  309 
Higashiyama et al. [46] investigated the effects of L-THE (200 mg) consumption on attention 310 
and reaction time responses in healthy university students with high and low anxiety propensities. The 311 
consumption of L-THE resulted in a decrease in HR (p=0.0016) and an improved reaction time 312 
response among high anxiety propensity participants compared to placebo. The STAI results indicated 313 
time dependant decrement patterns of anxiety; however, no differences were observed between groups, 314 
potentially attributing to the participants being familiar with the testing environment. Similarly, Rogers 315 
et al. [38] assessed anxiety interactions in 48 university students using a visual probing task. The 316 
consumption of L-THE slowed overall reaction time on the visual probe task, with social threat sub-317 
task reaction time (p=0.046), whereas no differences were observed in the physical threat reaction task 318 
(p=0.100) compared to placebo. The authors did attempt to discuss the potential mechanisms of action 319 
and reasons for not seeing anxiety lowering effects which were ascribed to participants being of a 320 
healthy mental state. 321 
The study by Kimura et al. [47] showed strong interactions between the perception of stress 322 
and state anxiety (p<0.01). The STAI scores were higher during the mental arithmetic task period than 323 
during the rest periods in the placebo group, but not in the other three conditions (p<0.01). The VAS 324 
scores were also lower in both L-THE conditions than under the two control conditions (p<0.01).  325 
In the study by White et al. [51] changes in brain alpha oscillatory activity, measured by 326 
electroencephalography and using resting-state recordings, were related to the potential anti-stress 327 
effects of L-THE supplementation. The results were higher in the L-THE treatment compared to the 328 
placebo for the high anxiety trait groups (p=0.019, one-tailed), while no changes were observed in the 329 
low anxiety group (p>0.1). It was suggested that the increase in resting alpha activity in the treatment 330 
group did not reflect the mechanism that normalises alpha activity in individuals with high anxiety. 331 
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Instead, the L-THE treatment enhances alpha oscillatory level activity selectively in individuals that 332 
self-reported higher levels of trait anxiety.  333 
The most prolonged (treatment duration) study by Sarris et al. [44] was an eight-week phase II 334 
randomised multicentre clinical trial in individuals (n=46) with generalised anxiety disorder. For the 335 
first four weeks, participants received 225 mg L-THE twice daily. After that, participants who were 336 
considered non-responders (based on HARS score), were prescribed double the original dose. Two 337 
measures were used to assess anxiety symptoms (HARS; BAI); however, neither doses of L-THE 338 
improved symptoms compared with placebo.  339 
In the study by Unno et al. [50], there was an association between STAI and subjective stress 340 
in the L-THE (p=0.012), but not in the placebo group. In the study by Yoto et al. [52] no differences 341 
between the groups were observed for VAS scores; however, the scores were lower in the L-THE 342 
group for tension-anxiety sub-scale of the POMS (p=0.004), representing a potential anxiolytic effect.   343 
 344 
Discussion 345 
The studies outlined in this systematic review indicate that L-THE supplementation has a potential 346 
anti-stress effect and anxiety suppressive properties at levels between 200-400 mg/day. All included 347 
articles demonstrate some strengths and indicators of quality, for instance, eight of the nine studies 348 
were designed as randomised, double-blind, placebo-controlled trials [38,44,46-49,51,52] while one 349 
study used a randomised, single-blind, placebo-controlled design [50]. However, according to the 350 
Cochrane assessment of the risk of bias, there was a lack of clarity in some domains of bias present in 351 
most studies.  352 
Given the duration of the Ritsner et al. [49] study, there appear to be no side effects of taking 353 
L-THE (400 mg/day) for 8 weeks. Furthermore, the study by Sarris et al. [44] with longer (10 weeks) 354 
and higher L-THE intake (900 mg) reported some adverse events in both groups (placebo and L-THE), 355 
but with no significant differences between groups. Considering that schizophrenia and schizoaffective 356 
15 
 
type of disorders are not acute types of mental health conditions, much longer L-THE trials may be 357 
required to establish the potential time/concentration side effects.  In addition, Ritsner et al. [49] 358 
demonstrated benefits of L-THE through the amelioration of psychotic and anxiety-related symptoms 359 
in contrast to the classical dopaminergic theory of psychosis [53].    360 
Consumption of L-THE was also proposed to affect the physiological biomarkers of stress. 361 
Elevated sAA is an indicator of autonomic nervous system excitation and was shown to be decreased 362 
prior to stress exposure in healthy participants following consumption L-THE [50]. Additionally, a 363 
previous study indicated that the consumption of L-THE was associated with improvements in sleep 364 
quality [54], which can be regulated through the sAA levels where participants with lower sAA levels 365 
had a longer sleep [50]. Once L-THE is consumed, it is absorbed within the intestinal lumen and 366 
transported to a range of tissues, including the brain within 10-24 min [55]. Therefore, it can be 367 
suggested that the results of the Unno et al. [50] study indirectly support the blood-brain-barrier 368 
passing of L-THE to illicit its psychological effects [50,55]. Therefore, consumption of L-THE may 369 
be an effective method for improvement in sleep quality without the increase in drowsiness. 370 
The L-THE consumption may also suppress excessive glutamatergic tone, which is implicated 371 
as a possible co-factor in increasing stress and its related anxiety responses [56,57]. The glutamatergic 372 
transmission relies on L-THE-mediated inhibition of neuronal glutamine uptake which, in turn, 373 
suppresses the conversion of glutamine to glutamate. Thus, the consequent decrease in glutamate 374 
release from the pre-synaptic terminals induced by L-THE represents another plausible mechanism 375 
contributing to the anti-stress and anti-anxiety effects (Figure 2) [50]. In addition, another mechanism 376 
putatively responsible for the inhibition of glutamatergic transmission is underpinned by the ability of 377 
L-THE to bind to the three glutamate receptor subtypes: Ar-methyl-D-aspartate (NMDA), amino-3-378 
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), and kainic acid (KA), thus competing with 379 
glutamate [58]. Moreover, in murine models, it has been shown that L-THE intake suppresses the HPA 380 
axis and behavioural depression [59], although the same mechanisms are yet to be demonstrated in 381 
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humans. Nevertheless, a study by Rogers et al. [38] suggested that L-THE may exhibit central 382 
monoaminergic and glutaminergic effects suggesting that slowing the reaction time on the visual probe 383 
task may also be attributed to the suppression of glutamate [50,58]. 384 
Although findings by Unno et al. [50] indicated that long-term use of L-THE could provide 385 
‘anti-stress’ effects. However, there was no indication this finding was a direct result of the daily intake 386 
of L-THE, a higher dose (400 mg), or a potential adaptive effect over several days [50]. Interestingly, 387 
in the study by Yoto et al. [52], consumption of 200 mg of L-THE reduced subjective stress and BP, 388 
but only in the short term. The study by Rogers et al. [38] indicated that L-THE could inhibit the 389 
caffeine-induced rise in BP, which is accompanied by increased nervousness and considered as a 390 
somatic symptom of anxiety. However, the DASS and STAI scores indicated participants were not 391 
prone to anxiety or stress. It was further proposed that the initial mental state of the participants might 392 
affect the reduction in anxiety caused by L-THE. However, this study speculates that tea is perceived 393 
to be more relaxing, partly due to the reason that L-THE reduces alertness/arousal and anxiety [38]. 394 
The effectiveness of L-THE in the acute anxiety induced conditions was also compared against 395 
the benzodiazepine alprazolam, a common pharmaceutical mediation used for the treatment of anxiety 396 
and related disorders [48]. Overall, neither L-THE nor alprazolam treatment resulted in any anxiolytic 397 
effects [48]. Despite this outcome, it seems that the intensity of anxiety was too great for L-THE to 398 
provide an anxiolytic effect; however, L-THE had a greater effect in the resting state of healthy 399 
individuals compared to participants with increased anxiety. Although alprazolam has shown some 400 
inconsistencies with reducing anxiety under resting conditions [60], Higashiyama et al. [46] 401 
highlighted that L-THE (200 mg) displayed positive effects relating to attentional performance as well 402 
as reaction time in a cohort prone to high anxiety. This can potentially indicate that L-THE may not 403 
be as effective in individuals that are not highly anxious. Furthermore, the results suggest a putative 404 
mechanism of action highlighted by the increase in alpha waves as determined by 405 
electroencephalogram [61]. This, in turn, supports the previous literature associating the relaxation 406 
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properties of L-THE with the increased synthesis of γ-aminobutyric acid, which plays a part in the 407 
stress response pertinent to dopamine and serotonin increase in the brain [58,61]. The study by Sarris 408 
et al. [44] of individuals with generalised anxiety disorder found no benefits using a high dose of L-409 
THE (450-900 mg), establishing that higher levels are potentially not beneficial in this type of a clinical 410 
sample. This was the first study to investigate the use of L-THE for the treatment of anxiety and sleep 411 
disturbance in generalised anxiety disorder and also the first to administer L-THE at doses higher than 412 
400 mg/day. Although L-THE appeared to improve self-reported sleep satisfaction in participants with 413 
generalised anxiety disorder, and insomnia symptoms in a sub-group of individuals with generalised 414 
anxiety disorder, this preliminary pilot study found no evidence of any beneficial effects of L-THE 415 
over the placebo in measures of anxiety and mood. Additionally, considering this trial used the highest 416 
amount of L-THE in the included studies, it appears that understanding how high levels L-THE affects 417 
the psychological response is still relatively unexplored. 418 
Lastly, the study by White et al. [51] reported a decrease in the stress response post 419 
consumption of a nutrient-based drink containing 200 mg L-THE in response to a cognitive stressor 420 
task. The results indicated that the anti-stress response is attributed to a decrease in salivary cortisol 421 
only in 3 hr post-dosage. The authors reported no differences in cognitive performance, although 422 
posterior alpha oscillatory activity was found to be higher in participants exhibiting higher trait anxiety 423 
participants but was not associated with the other anti-stress outcomes. This study was limited as the 424 
active treatment that contained L-THE (200 mg) contained other ingredients: L-alpha 425 
glycerylphosphorylcholine (25 mg), phosphatidylserine (1 mg) and micronized chamomile (10 mg) 426 
that were unique to the active treatment and not the placebo. Although the beneficial effects of L-THE 427 
were observed after post-consumption, the authors acknowledged that an additional arm of treatment 428 
was needed to evaluate consumption of other ingredients in the nutrient drink as they may interact with 429 
L-THE absorption. 430 
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Thus, in a setting where green tea consumption frequently occurs, as opposed to pure L-THE 431 
consumption (4-8 cups/day; 150-200 mg), it is difficult to accurately measure the causative agent for 432 
specific physiological and psychological outcomes, as green tea contains a number of polyphenolic 433 
compounds (catechins) that might also interfere with the aforementioned health outcomes [16,24]. 434 
Indeed, studies have found tea drinkers have lower levels of depressive symptoms [62]; however, it is 435 
difficult to identify the lead potential anti-depressive agent due to the other bioactive compounds in 436 
green tea such as catechins. It is reported that the consumption of green tea in general or with other 437 
constituents may affect the uptake of other compounds, such as vitamin B1 [63], interference of lipid 438 
digestion due to green tea catechins [64] as well as the inhibiting effects L-THE shows in the presence 439 
of caffeine [29].  Similarly, the presence of L-THE in the blood has previously been shown to decrease 440 
the uptake of branched-chain amino acids, such as leucine, isoleucine and valine [36]; however, this 441 
mechanism is yet to be elucidated in humans.  442 
 443 
Future directions 444 
Given the growing interest and prevalence of green tea bioactives consumption globally [23], future 445 
human trials of L-THE consumption should be conducted over a more extended period (ten weeks or 446 
longer) with the combination in identifying the therapeutic doses required for different population sub-447 
groups. The effect of L-THE in clinical practice focusing on the type of specific clinical population 448 
may, in turn, affect cardiovascular outcomes with potentially beneficial outcomes. Currently, the 449 
consumption of L-THE is associated the of a relaxed but alert state, providing the basis of L-THE use 450 
as a nutraceutical with stress- and anxiety-reducing properties. Moreover, the use of L-THE with other 451 
nutraceuticals (i.e. B-vitamins) may have positive synergistic effects on anxiety, stress, depressive 452 
symptoms, and cognition [65,66]. Further, studies should be conducted to ascertain whether L-THE 453 
binds to food matrixes before consumption as the health effects of L-THE may vary depending on the 454 





The supplementation of L-THE in its pure form at dosages between 200–400 mg/day may help reduce 458 
stress and anxiety acutely in people undergoing acute stressful situations, but there is insufficient 459 
evidence to suggest it assists in the reduction of stress levels in people with chronic conditions. 460 
However, the results of this study suggest that L-THE taken during times of heightened acute stress or 461 
by individuals with a high propensity for anxiety and stress may exhibit beneficial properties via the 462 
increased production of alpha waves and decrease of glutamate in the brain.  463 
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Figures and Tables 629 
 630 
Fig 1 PRISMA flowchart of search strategy and selection of relevant studies.  631 
 632 
Fig 2 L-THE may reduce the binding of glutamine to glutamate receptors (mGLU) inhibiting the 633 
incorporation of extracellular glutamine into the neuron (A). This may prevent the formation of 634 
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Table 2. Summary of risk of bias assessment of included studies 642 
 Higashiyama 
et al. (2011) 
Kimura et al. 
(2006) 
Lu et al. 
(2004) 
Ritsner et al. 
(2011) 
Rogers et al. 
(2008) 
Sarris et al. 
(2018) 
Unno et al. 
(2013) 
Yoto et al. 
(2012) 
White et al. 
(2016) 
Random sequence generation 
(selection bias) 
Unclear Low Low Low Unclear Low Low Low Low 
Allocation concealment (selection 
bias) 
Low Low Low Low Low Low Low Unclear Low 
Blinding of participants and personnel 
(performance bias) 
Low Low Low Low Low Low High
†
 Unclear Low 
Blinding of outcome assessment 
(detection bias) (patient-reported 
outcomes) 
Unclear Unclear Unclear Unclear Low Low High
†
 Unclear Unclear 
Blinding of outcome assessment 
(detection bias) (Mortality) 
Low Low Low Low Low Low Low Low Low 
Incomplete outcome data addressed 
(attrition bias)   
Low Low Low Low Low Low Low Low Low 
Selective reporting (reporting bias) Low Low Low Low Low Low Low Low Low 
† This study was single-blinded  643 
